| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/20/2023 | 12.99% | Wedbush | → $2 | Downgrades | Outperform → Neutral |
| 10/30/2023 | — | Leerink Partners | Downgrades | Outperform → Market Perform | |
| 10/12/2023 | 634.46% | Citigroup | → $13 | Initiates Coverage On | → Buy |
| 09/13/2023 | — | Guggenheim | Downgrades | Buy → Neutral | |
| 09/13/2023 | 182.49% | Goldman Sachs | → $5 | Downgrades | Buy → Neutral |
| 09/12/2023 | — | Guggenheim | Downgrades | Buy → Neutral | |
| 08/15/2023 | 1368.93% | Guggenheim | $27 → $26 | Maintains | Buy |
| 08/15/2023 | 1255.93% | Goldman Sachs | $27 → $24 | Maintains | Buy |
| 07/28/2023 | 1142.94% | Wedbush | $26 → $22 | Maintains | Outperform |
| 07/28/2023 | 634.46% | Morgan Stanley | $25 → $13 | Downgrades | Overweight → Equal-Weight |
| 07/20/2023 | 1312.43% | Morgan Stanley | $28 → $25 | Maintains | Overweight |
| 05/18/2023 | 1368.93% | Wedbush | → $26 | Reiterates | Outperform → Outperform |
| 05/15/2023 | 1368.93% | Wedbush | → $26 | Reiterates | Outperform → Outperform |
| 03/17/2023 | 1086.44% | Wedbush | $28 → $21 | Maintains | Outperform |
| 01/24/2023 | 1481.92% | Morgan Stanley | $29 → $28 | Maintains | Overweight |
| 01/20/2023 | 1481.92% | Goldman Sachs | $25 → $28 | Maintains | Buy |
| 01/10/2023 | 1820.9% | SVB Leerink | $41 → $34 | Maintains | Outperform |
| 11/08/2022 | 1538.42% | Morgan Stanley | $27 → $29 | Maintains | Overweight |
| 11/08/2022 | 2216.38% | SVB Leerink | $42 → $41 | Maintains | Outperform |
| 10/31/2022 | 1594.92% | Guggenheim | → $30 | Initiates Coverage On | → Buy |
| 08/15/2022 | 1425.42% | Morgan Stanley | $28 → $27 | Maintains | Overweight |
| 07/15/2022 | 1481.92% | Morgan Stanley | $31 → $28 | Maintains | Overweight |
| 05/17/2022 | 1651.41% | Morgan Stanley | $36 → $31 | Maintains | Overweight |
| 05/02/2022 | 1368.93% | Goldman Sachs | → $26 | Initiates Coverage On | → Buy |
| 02/10/2022 | 2046.89% | SVB Leerink | → $38 | Initiates Coverage On | → Outperform |
| 01/06/2022 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 11/08/2021 | 3967.8% | Morgan Stanley | → $72 | Initiates Coverage On | → Overweight |
| 11/08/2021 | 2159.89% | Wedbush | → $40 | Initiates Coverage On | → Outperform |
What is the target price for 2seventy bio (TSVT)?
The latest price target for 2seventy bio (NASDAQ: TSVT) was reported by Wedbush on November 20, 2023. The analyst firm set a price target for $2.00 expecting TSVT to rise to within 12 months (a possible 12.99% upside). 17 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for 2seventy bio (TSVT)?
The latest analyst rating for 2seventy bio (NASDAQ: TSVT) was provided by Wedbush, and 2seventy bio downgraded their neutral rating.
When is the next analyst rating going to be posted or updated for 2seventy bio (TSVT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of 2seventy bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for 2seventy bio was filed on November 20, 2023 so you should expect the next rating to be made available sometime around November 20, 2024.
Is the Analyst Rating 2seventy bio (TSVT) correct?
While ratings are subjective and will change, the latest 2seventy bio (TSVT) rating was a downgraded with a price target of $0.00 to $2.00. The current price 2seventy bio (TSVT) is trading at is $1.77, which is within the analyst's predicted range.